Protagenic Therapeutics, Inc. (PTIX) Company Value to Net Income

Corporate emblem and logo of Protagenic Therapeutics, Inc. (PTIX)

This chart of the P/E ratio history for Protagenic Therapeutics (PTIX) currently shows a level of -0.20. Protagenic Therapeutics is implementing software robots to process CNS data arrays and is testing automated screening stations. The business relies on bioinformatics IT platforms to create synthetic neuropeptides, eliminating routine tasks for personnel. The development of treatments for anxiety and depression is being conducted in collaboration with leading neurobiological centers.

PTIX Protagenic Therapeutics Inc.: Price to Earnings Ratio in the range 07/04/2022 - 01/10/2026

Comprehensive metric breakdowns and analytics for Protagenic Therapeutics Inc. (PTIX)

- stock price and consensus target price:
Quote Chart Protagenic|PTIX - Price Target Chart
- market capitalization details:
Market Value Protagenic Therapeutics, Inc.|PTIX - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Protagenic Therapeutics|PTIX - Company Net Assets|Market Cap to Book Value Multiple protagenic.com|PTIX - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital Protagenic Therapeutics|PTIX - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Protagenic|PTIX - Company Aggregate Debts|Debts to Book Value Protagenic Therapeutics, Inc.|PTIX - Company Long-Term Debt|Company Short-Term Indebtedness Protagenic Therapeutics|Interim Coverage Ratio protagenic.com
- business earnings and investment ratios data:
PTIX - Net Profit|Future Profit Protagenic Therapeutics|PTIX - Price to Earnings Ratio|Future Price to Earnings Multiple Protagenic|PTIX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Protagenic Therapeutics, Inc.|PTIX - Operating profit EBITDA|Earnings per share for the trailing year Protagenic Therapeutics|PTIX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months protagenic.com|PTIX - Earnings per share growth in current year|Expected earnings per share trend next year Protagenic Therapeutics
Summary company analysis:PTIX (protagenic.com)
Core merchandise of Protagenic

Protagenic Therapeutics (PTIX) develops neuroactive peptides for the treatment of depression and anxiety disorders. The P/E ratio relates the current market value of a share to the net profit per share. By analyzing the historical P/E dynamics of Protagenic Therapeutics (PTIX), an investor determines the payback period of the investment. This marker measures market expectations regarding the issuer's future cash flows. Low values may signal undervaluation or fundamental business risks.

Analysis of competing companies

biogen.com - Market Cap to Net Income|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|RGC (Regencell Bioscience Ltd) - Company Value to Net Income|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACADIA Corp (ACAD) - Market Cap to Earnings|XENE: Price to Earnings Ratio|vikingtherapeutics.com - Market Price to Net Income Ratio|SUPN: P/E Multiple|Catalyst Pharma (CPRX) - P/E Multiple|DNLI (Denali Therapeutics Inc) - P/E Multiple|HRMY - Market Cap to Net Income Ratio|P/E Multiple BHVN|AMLX - Market Cap to Earnings|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|PRAX: Price to Earnings Multiple|Anavex Corp - P/E Multiple|Business Payback Period CeriBell EEG CBLL|PRTA: P/E Multiple|Price to Earnings Ratio Alector|Price to Earnings Ratio ANNX|OMER: Company Value to Net Income|Price to Earnings Ratio NGNE (Neurogene Corp)|Market Price to Net Income Ratio ACIU|P/E Multiple VYGR (Voyager Therapeutics)|Company Value to Net Income NMRA|Scilex - P/E Multiple|Market Cap to Earnings Tevogen Bio Holdings Inc.|alphacognition.com (ACOG) - Price to Earnings Ratio|Cognition Therapeutics Inc. - Company Value to Net Income|IKT (Inhibikase Therapeutics) - P/E Multiple|P/E Multiple cassavasciences.com|Price to Earnings Ratio Assertio Holdings, Inc. (ASRT)|COYA: Market Cap to Net Income|P/E Multiple VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Market Cap to Earnings|ABOS: Price to Earnings Ratio|CRVO - P/E Multiple|ATHE (alteritytherapeutics.com) - Price to Earnings Ratio|CLNN: Market Price to Net Income Ratio|PEPG (PepGen Inc) - P/E Multiple|Jupiter Neurosciences, Inc. (JUNS) - Business Payback Period|P/E Multiple RLMD|Price to Earnings Ratio annovisbio.com ANVS|Price to Earnings Ratio Grace Therapeutics GRCE|Business Payback Period Firefly Neuroscience, Inc. (AIFF)|KLTO - Price to Earnings Ratio|Market Cap to Net Income NRSN|RVPH (Reviva Pharmaceuticals) - Price to Earnings Ratio|MTVA: Market Price to Net Income Ratio|NRXS (NeurAxis) - P/E Multiple|Helius Medical Technologies Inc. (HSDT) - Business Payback Period|Price to Earnings Ratio PASG (Passage Bio, Inc.)|bionomics.com.au - Price to Earnings Multiple|Price to Earnings Ratio Minerva Neurosciences NERV|ATHA: Price to Earnings Multiple|Addex Therapeutics Ltd - P/E Multiple|Market Cap to Earnings Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Price to Earnings Ratio|Pasithea Therapeutics Corp. (KTTA) - P/E Multiple|Price to Earnings Ratio Cortigent Inc|ATXI: Company Value to Net Income|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|CARA - Market Cap to Earnings|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|ELYM (Eliem Therapeutics, Inc.) - Market Cap to Net Income|ITCI - Price to Earnings Ratio|Company Value to Net Income LBPH (longboardpharma.com)|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|Market Cap to Earnings NKGen Biotech Inc (NKGN)|Price to Earnings Ratio NRBO|SAGE (Sage Therapeutics Inc) - Market Price to Net Income Ratio|P/E Multiple SNPX|P/E Multiple trevena.com (TRVN)|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|Market Cap to Net Income Ratio anewmeds.com|Cerevel - P/E Multiple